Mr. Dave Ryan reports

BIOHARVEST SCIENCES ANNOUNCES CONVERSION OF DEBT NOTES

Bioharvest Sciences Inc. has completed an early conversion of convertible debt notes, associated with the convertible debt financing rounds completed in October, 2022, November, 2022, July, 2023, October, 2023, and December, 2023. Bioharvest reports that a total of $16,742,435.22 (principal loans plus accrued interest) has been converted into 73,268,708 common shares. As part of the term of 2023 convertible loans, the company issued 39,775,554 early exercise warrants at three cents for early conversion. A total of 34,563,008 early exercise warrants will expire on Oct. 30, 2025, and 5,212,546 will expire on Dec. 22, 2025.

About Bioharvest Sciences Inc.

Bioharvest Sciences is a leader in botanical synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. Bioharvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements.

We seek Safe Harbor.